Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 17,755 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Communication
Interventions: First year program, Control comparison; Behavioral · Other
Lead sponsor: Jennifer McCallister MD; Other
Eligibility: 18 Years to 89 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cataract
Interventions: Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Overweight and Obesity, Pre-diabetes
Interventions: learning modules (within app), SWITCH app (self-regulation features) - Experimental, SWITCH app (self-regulation features) - Comparator; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions: PN-943, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 31
States / cities: Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Elective Cesarean Section, Pain Management
Interventions: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg, Phenazopyridine Hydrochloride Tables, USP 200 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Port Jefferson, New York

Conditions: Depression
Interventions: Positive affect treatment, Supportive psychotherapy (SUP); Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years to 16 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Irvine, California

Conditions: Cancer, Depression, PostTraumatic Stress Disorder, Anxiety
Interventions: FOCUS Resilience Enhancement Program, Waitlist (No Study Treatment); Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis of the Wrist
Interventions: adipose-derived stem cell injection, Corticosteroid injection; Device · Drug
Lead sponsor: InGeneron, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Sioux Falls, South Dakota • Houston, Texas

Conditions: Pre-hypertension
Interventions: AI-Based Lifestyle Recommendations, No Lifestyle Recommendations; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Osteoarthritis of the Knee
Interventions: Apitox, purified honeybee toxin, lyophilized in saline, histamine; Biological
Lead sponsor: Apimeds, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Gulf Shores, Alabama • Tucson, Arizona • Garden Grove, California + 11 more

Conditions: Knee Injury
Interventions: J-Tip, Syringe and 25 gauge needle; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Osteoarthritis of Facet Joint of Lumbar Spine
Interventions: Adipose-derived stem cell injection, Corticosteroid injection; Device · Drug
Lead sponsor: InGeneron, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Deerfield Beach, Florida • Sioux Falls, South Dakota

Conditions: Healthy Adults
Interventions: EC5026 oral capsule, Placebo oral capsule; Drug · Other
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Psilocybin
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 1 Diabetes
Interventions: Control, Study Arm B; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Inflammation, Pain, Cataract
Interventions: XG-102, Placebo; Drug
Lead sponsor: Xigen SA; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Alcoholism
Interventions: Daily monitoring of alcohol & drug use, & therapy skills, control group; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 19 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Diet, Mediterranean, Health Behavior, Program Sustainability, Program Effectiveness
Interventions: Mediterranean diet Intervention; Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Electronic Medication Monitors on ICS and SABA - Active Mode, Electronic Medication Monitors on ICS and SABA - Silent Mode, Asthma App Tracking of ICS/SABA Usage - Active Mode, Asthma App Tracking of ICS/SABA Usage - Silent Mode, NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes, NorthShore Connect Real Time ICS and SABA Usage Feedback - No, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes, Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No; Behavioral
Lead sponsor: Endeavor Health; Other
Eligibility: 25 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Dentin Sensitivity
Interventions: Stannous fluoride toothpaste, Crest cavity protection toothpaste; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Pain
Interventions: Green light, Clear light, Blue Light; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: PreDiabetes
Interventions: Avocado, low fat yogurt, low fat yogurt + fiber +fat; Other
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

SWITCH Diets Study: Self-monitoring With Internet Technology to Choose Healthy Diets

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Positive Affect Treatment for Adolescents With Early Life Adversity

FOCUS:Families OverComing Under Stress

Healing Osteoarthritic Joints in the Wrist With Adult ADRCs

Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence

Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis

Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy

Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

Precision Functional Brain Mapping in Psilocybin

Timing of Insulin Before Meals Everyday

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Using Telephone Technology to Prevent Relapse After Alcoholism Treatment

Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits

The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma

Clinical Study to Evaluate the Anti-sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers

Opioid Sparing Potential of Light-Induced Analgesia

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Avocado Snacks in a Prediabetic Population